title: Management of immune thrombocytopenic purpura in children: potential role of novel agents.
abstract: The treatment of immune thrombocytopenic purpura (ITP) in children is controversial, requiring individualized assessment of the patient and consideration of treatment options. If the platelet count is >10 000/μL and the patient is asymptomatic, a 'watch and wait' strategy is appropriate since most children with ITP will recover completely without pharmacotherapy. If therapy is indicated because of bleeding or a platelet count <10 000/μL, then treatment with glucocorticoids, intravenous immunoglobulin (IVIg), or anti-D are possible initial choices. Glucocorticoid treatment is the least expensive and is our usual first choice of therapy. Its use assumes that the blood counts and blood film have been evaluated to ensure the absence of evidence of alternative diagnoses, such as thrombotic thrombocytopenic purpura or incipient acute leukemia. IVIg is expensive and often causes severe headache, nausea and vomiting, and requires hospitalization at our institution. Anti-D therapy is also expensive and can only be used in patients who are Rhesus D positive. These therapies, even if only transiently effective, can be repeated if necessary. Children usually recover from newly diagnosed ITP, with or without multiple courses of medical therapy. If the disease becomes 'persistent' with severe thrombocytopenia and/or bleeding, and is no longer responsive to the three first-line therapies, the next approach includes the use of thrombopoietin receptor agonists or rituximab. When the disease persists for more than 1 year, it is considered chronic, and, if symptomatic, it may become necessary to consider third-line therapies, including splenectomy, alternative immunosuppressive agents, or combination or investigative chemoimmunotherapy. This review considers the indications, mechanism of action, and effectiveness of the traditional and novel treatment options for patients with ITP.
authors.affiliation: Department of Pediatrics, Division of Hematology/Oncology, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA. amy-lee_bredlau@urmc.rochester.edu
authors.forename: Amy Lee
authors.initials: AL
authors.lastname: Bredlau
authors.forename: John W
authors.initials: JW
authors.lastname: Semple
authors.forename: George B
authors.initials: GB
authors.lastname: Segel
mesh_terms: D000818:Animals; D002648:Child; D016527:Drug Costs; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007518:Isoantibodies / Q000191:economics / Q000276:immunology / Q000627:therapeutic use; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology / Q000628:therapy*; D018029:Rho(D) Immune Globulin; D013156:Splenectomy / Q000379:methods
chemical_list: D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin